A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs MK 4280 (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms MK-4280-001
- Sponsors Merck Sharp & Dohme
- 05 Aug 2017 Planned number of patients changed from 260 to 240.
- 17 Apr 2017 Planned number of patients changed from 70 to 260.
- 23 Jan 2017 Planned End Date changed from 1 Aug 2020 to 1 Oct 2020.